WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524264
CAS#: 108427-72-1
Description: AS 35 is an antiallergic drug. AS-35 controls allergic diseases by inhibiting eosinophil activation.
Hodoodo Cat#: H524264
Name: AS-35
CAS#: 108427-72-1
Chemical Formula: C21H20N6O4
Exact Mass: 420.15
Molecular Weight: 420.420
Elemental Analysis: C, 59.99; H, 4.79; N, 19.99; O, 15.22
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AS 35; AS35; AS-35;
IUPAC/Chemical Name: 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-
InChi Key: RVRGDCZGEKSIRW-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H20N6O4/c1-3-5-15-17(8-7-14(12(2)28)18(15)29)31-11-13-6-4-9-27-20(13)22-10-16(21(27)30)19-23-25-26-24-19/h4,6-10,29H,3,5,11H2,1-2H3,(H,23,24,25,26)
SMILES Code: c12ncc(c(n1cccc2COc1c(c(c(cc1)C(=O)C)O)CCC)=O)c1nnn[nH]1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 420.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Kozloski GD, De Vito JM, Johnson JB, Holmes GB, Adams MA, Hunt TL. Bioequivalence of verapamil hydrochloride extended-release pellet-filled capsules when opened and sprinkled on food and when swallowed intact. Clin Pharm. 1992 Jun;11(6):539-42. PubMed PMID: 1600686. 1: Khan P, Saxena T, Adarsh KV. Tailoring between network rigidity and nanosecond transient absorption in a-Ge(x)As(35-x)Se₆₅ thin films. Opt Lett. 2015 Mar 1;40(5):768-71. doi: 10.1364/OL.40.000768. PubMed PMID: 25723428.
2: Khan P, Jain H, Adarsh KV. Role of Ge:As ratio in controlling the light-induced response of a-Ge(x)As(35-x)Se65 thin films. Sci Rep. 2014 Feb 7;4:4029. doi: 10.1038/srep04029. PubMed PMID: 24504158; PubMed Central PMCID: PMC3916963.
3: van Leeuwen R, Chakravarthy U, Vingerling JR, Brussee C, Hooghart AJ, Mulder PG, de Jong PT. Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? Ophthalmology. 2003 Aug;110(8):1540-4. PubMed PMID: 12917169.
4: Hamasaki Y, Zaitu M, Tsuji K, Miyazaki M, Hayasaki R, Muro E, Yamamoto S, Kobayashi I, Matsuo M, Ichimaru T, Miyazaki S. (9-[4-acetyl-3-hydroxy-2-n-propylphenoxy) methyl]-3-(1H-tetrazol-5-yl)-4H-pyrido [1,2-a] pyrimidin-4-one), AS-35, inhibits leukotriene synthesis. Int J Immunopharmacol. 2000 Jul;22(7):483-90. PubMed PMID: 10785545.
5: Owens DR, Gibbins RL, Lewis PA, Wall S, Allen JC, Morton R. Screening for diabetic retinopathy by general practitioners: ophthalmoscopy or retinal photography as 35 mm colour transparencies? Diabet Med. 1998 Feb;15(2):170-5. PubMed PMID: 9507921.
6: Kawashima T, Nagaki S, Iwakaji A, Iwamoto I, Yoshida S, Tomioka H. [Inhibitory effect of AS-35. a novel antiallergic drug, on chemical mediator release from human eosinophils]. Arerugi. 1994 Dec;43(11):1326-30. Japanese. PubMed PMID: 7887808.
7: Takata H, Tamura G, Shibasaki A, Honma M, Takishima T. [Effect of AS-35 aerosol on bronchoconstriction induced by specific antigens in macacus rhesus monkeys]. Arerugi. 1993 Jul;42(7):870-7. Japanese. PubMed PMID: 7689825.
8: Watanabe-Kohno S, Yasui K, Ohkawa E, Yamamura H, Horiba M, Inoue K, Ohata K. Effect of AS-35 on agonist-induced contractions and the resting tonus of airway smooth muscles and the in vitro release of chemical mediators from passively sensitized lung fragments from humans and guinea pigs. Jpn J Pharmacol. 1992 Jun;59(2):227-33. PubMed PMID: 1279252.
9: Kasai H, Yanagihara Y. Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64. PubMed PMID: 1405033.
10: Kasai H, Kawashima T, Omura S, Yanagihara Y. Peptide leukotriene antagonistic activity of AS-35, a new antiallergic drug. Jpn J Pharmacol. 1992 Apr;58(4):347-55. PubMed PMID: 1405032.
2: Christrup LL, Bonde J, Rasmussen SN, Rassing MR. Relative bioavailability of (+/-)-verapamil hydrochloride administered in tablets and chewing gum. Acta Pharm Nord. 1990;2(6):371-6. PubMed PMID: 2095796. 3: Marvola M, Kannikoski A, Taskinen J, Ottoila P. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique. J Pharm Pharmacol. 1985 Nov;37(11):766-70. PubMed PMID: 2867156.